Kiniksa Pharmaceuticals International, PLC
Clinical trials sponsored by Kiniksa Pharmaceuticals International, PLC, explained in plain language.
Biopharmaceutical company focused on inflammatory and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New shot aims to stop repeat heart sac inflammation
Disease control Recruiting nowThis study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have sympt…
Phase 2/3 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New shot aims to keep pericarditis Flare-Ups at bay
Disease control Recruiting nowThis study tests a new drug called KPL-387 in 80 people with well-controlled recurrent pericarditis (inflammation around the heart). The goal is to see if patients can safely switch from their current treatments to KPL-387 alone and still prevent flare-ups. The trial will measure…
Phase 2 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC